Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial Financial Postsource Post navigation Calls to Poison Centers Involving Psilocybin Rising in Youth – Psychiatry OnlinePsyence Group Advances Psilocybin Clinical Trial – TipRanks